theMednetRegister

Dermatology

Medical Oncology   

Questions discussed in this category

Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
Are there other settings where MRI is used for nerve assessment and radiation planning such as for certain definitive RT cases?
4 Answers available
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Would you hypofractionate or be more conservative at 2 Gy per fraction? Would your management be affected knowing the patient is on hydroxyurea?
8 Answers available
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
2 Answers available
When would you recommend adjuvant radiation therapy for a patient with a completely resected (negative margins) dermatofibrosarcoma protuberans?
4 Answers available
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Would your management change given that this recurrent lesion is over 10 cm and the patient previously achieved complete response on immunotherapy 5 y...
3 Answers available
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
2 Answers available
Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?
4 Answers available
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
4 Answers available
Do you offer adjuvant radiation therapy for a breast cancer patient with dermatomyositis?
If so, what dose-fractionation do you utilize? What other factors do you take into consideration?
2 Answers available
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
2 Answers available
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
Should we switch to a new TKI?
1 Answer available
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
Is T4 disease a contraindication?
1 Answer available
What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?
2 Answers available
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
1 Answer available
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
Is completing nodal dissection warranted for surgical management?
1 Answer available
How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?
The SWOG 1801 trial showed improved event-free survival (EFS) in patients receiving neoadjuvant pembrolizumab followed by 15 cycles of adjuvant pembro...
1 Answer available
How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?
Very-low-risk stage IIIA disease includes non-ulcerated lesions, primary ≤2 mm thickness, SLN metastasis <1 mm. Per NCCN the toxicity of adjuvan...
1 Answer available
What surveillance plan would you recommend for stage IV melanoma patients who achieve a CR or stable PR response with immunotherapy?
1 Answer available
How do you approach patients with metastatic uveal melanoma not a candidate for tebentafusp-tebn? 
2 Answers available
Will you be offering patients urea-based creams or topical diclofenac for hand-foot prophylaxis with capecitabine after the D-TORCH trial results?
D-TORCH compared topical diclofenac to placebo
3 Answers available
How do you approach patients with polypoid/nodular melanoma for adjuvant therapy when Breslow depth is not available on pathology?
In this scenario do we use the actual tumor size for "T staging".
2 Answers available
How do you approach the management of basal cell carcinoma with single lymph node involvement?
In patients with no apparent skin involvement but lymph-node showing basal cell carcinoma with extracapsular extension. Would this warrant radiation o...
3 Answers available
Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?
Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?
4 Answers available
Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?
Do you base your decision on extent of residual disease?  Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...
4 Answers available
Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?
Is a placebo-controlled trial anticipated?
6 Answers available
Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?
3 Answers available
How do you approach balancing the potential risk of worsening actinic damage and maintaining CTCL clearance in patients treated with nb-UVB?
2 Answers available
How do you approach patients with a new primary melanoma, not an in-transit metastasis, while on adjuvant immunotherapy/treatment for a previous melanoma lesion?
2 Answers available
How do you approach patients with early stage resected melanoma (Stage IIA) for adjuvant treatment?
1 Answer available
What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?
3 Answers available
How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?
If the patient had no nodal sampling, would this influence your decision?
1 Answer available
In what scenario would you add systemic therapy with adjuvant radiation therapy in resected, locally-advanced, cutaneous squamous cell carcinoma?
Reference: TROG 05.01 Trial
1 Answer available
Do you get routine MRI brain for surveillance on patients with history of stage III melanoma?
2 Answers available
What advice do you have for the management of nail toxicity associated with pemigatinib and other FGFR inhibitors?
1 Answer available
In which clinical situations, if any, would you use imiquimod for treatment of breast cancer skin metastases?
1 Answer available
What clinical or pathologic features would make you more concerned that a new skin SCC is from metastatic disease or a new cutaneous primary?
1 Answer available
When do you order genetic studies such as comparative genomic hybridization for melanocytic lesions?
1 Answer available
Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?
2 Answers available
Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?
6 Answers available
What methods do you use to prophylactically reduce radiation dermatitis for head and neck irradiation?
4 Answers available
What first-line therapies do you recommend for patients with folliculotropic mycosis fungoides?
Has topical dapsone worked? 
3 Answers available
Is oral lichen planus a contraindication for immunotherapy in a patient with recurrent oral SCC?
There have been reports of pembrolizumab leading to lichen planus (my understanding is lichen planus pathophysiology unclear, but potentially autoimmu...
1 Answer available
Can you continue checkpoint inhibitor therapy in the setting of severe cutaneous irAE while concurrently treating the cutaneous reaction?
2 Answers available
What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?
2 Answers available
Do you ever offer scalp cooling therapy to metastatic breast cancer patients wishing to avoid alopecia?
1 Answer available
How do you manage patients with chemotherapy-induced paronychia?
1 Answer available
How would you manage a patient with essential thrombocythemia and persistent pruritus despite adequate control of CBC with hydroxyurea and aspirin?
ET is JAK2+
1 Answer available
How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?
Do you have a preferred sequence of therapies for diffuse skin limited MF?
1 Answer available
Would you still consider durvalumab consolidation after definitive chemoradiation for patients with Stage III NSCLC who are on stable weekly methotrexate dosing for psoriasis/psoriatic arthritis?
1 Answer available
How would you manage a nodal recurrence of cutaneous SCC if the patient is unable to receive surgery for 6-8 weeks?
In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...
1 Answer available
How would you approach an early inguinal recurrence after surgical resection of Merkel Cell carcinoma in the popliteal region?
2 Answers available
Is there a role for adjuvant systemic therapy (in addition to adjuvant radiation) in an early-stage, resected cutaneous angiosarcoma of the head/neck?
Post-auricular cutaneous angiosarcoma, pT1 (19 mm) with negative margins. Unclear if there is any indication for systemic therapy, given early stage a...
1 Answer available
What type of surveillance would you recommend following resection of primary mucinous carcinoma of the skin?
1 Answer available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available
Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?
1 Answer available
How do you manage docetaxel or other taxane-induced nail toxicity?
e.g., subungual hemorrhage and onycholysis?
1 Answer available
How do your adjuvant treatment recommendations change, if at all, for clinically node positive Stage III desmoplastic melanoma?
1 Answer available


Papers discussed in this category

International journal of radiation oncology, biology, physics, 2013-07-01
Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
JAMA oncology, 2017-07-01
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Melanoma research, 2015-04
The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.
Nature, 2018-01-18
High response rate to PD-1 blockade in desmoplastic melanomas.
Cureus, 2019 Jun 18
Desmoplastic Melanoma: Clinical Characteristics and Survival in the US Population.
PloS one, 2015
Clinicopathologic predictors of survival in patients with desmoplastic melanoma.
Cancer,
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot.
Eur J Oncol Nurs, 2011 Jul 23
Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity.
Support Care Cancer, 2013 Dec 22
Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial.
Breast Cancer Res. Treat., 2017 May 09
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
N Engl J Med, 2022 Sep 12
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Front Oncol, 2023 Jan 04
Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.
Br J Dermatol, 2015 Aug 08
Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.
Head Neck, 2021 Jun 07
Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review.
J Immunother Cancer,
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
J Immunother Cancer,
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Mod Pathol, 2020 Feb 17
DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach.
Melanoma research, 2017-10
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
Cancer, 2011-04-15
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 Sep 09
Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment.
Medicine (Baltimore), 2019 Dec
Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas.
J Clin Invest, 2013 Nov 15
Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice.
European journal of cancer (Oxford, England : 1990), 2017-04
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
American journal of clinical oncology, 2005-12
Head and neck mucosal melanoma.
Head & neck, 2016-01
Update on primary head and neck mucosal melanoma.
The Laryngoscope, 1994-02
Mucosal melanoma of the head and neck: the impact of local control on survival.
Oral and maxillofacial surgery, 2023 Apr 05
Head and neck mucosal melanoma: radiological considerations and UK imaging guidelines.
Oncologist, 2020 Oct 28
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
JAMA Dermatol, 2017 Jul 01
Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.
J. Clin. Oncol., 2018 Mar 14
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.
The New England journal of medicine, 2017-11-09
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med, 2018 Apr 15
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Oct 30
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Dec 01
Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.
Cancer, 2023 Mar 04
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Journal for immunotherapy of cancer, 2022 Aug
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
N Engl J Med, 2017 Jun 8
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
Current oncology (Toronto, Ont.), 2015 Apr
Management of egfr tki-induced dermatologic adverse events.
Journal of the American Academy of Dermatology, 2019 Dec 10
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
The oncologist, 2021 May 31
Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
Lancet Oncol, 2022 Oct 18
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Journal of the American Academy of Dermatology, 2023 Dec 07
Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: A retrospective cohort study.
JAMA dermatology, 2020 May 01
Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy.
Photodermatology, photoimmunology & photomedicine, 2023 Dec 07
Frequency of skin cancer among psoriasis, vitiligo, and mycosis fungoides patients treated with narrowband ultraviolet B phototherapy.
Clinical and experimental dermatology, 2024 Apr 23
Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Apr 17
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
N Engl J Med, 2023 Mar 2
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
The New England journal of medicine, 2024 Jun 02
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Cancer cell, 2022 May 09
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
The New England journal of medicine, 2018-07-26
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016 Jul 27
Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure.

Related Topics in Dermatology

Copyright © 2024 theMednet
All Rights Reserved.